Home

Latest News

Luncheon with the Experts in NYC for Carcinoid and Neuroendocrine Tumor Patients

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015. There is no charge for the luncheon thanks to the generous sponsorship of Lexicon Pharmaceuticals.  Read more

Help Us to Help You

The Carcinoid Cancer Foundation is always looking at ways of improving content and services available to people living with carcinoid cancer and other neuroendocrine tumors and we are working with a pharmaceutical partner, Ipsen, to better understand what resources, information, and support you would like to see made available at each stage of your journey. Read more

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Read more

Surviving Carcinoid Cancer for More Than 3 Decades

Marilyn Thurston of Colorado may be the longest-surviving carcinoid patient in the United States and possibly the world, having been diagnosed over 30 years ago.  Her physician, Dr. Nicholas DiBella, created a special pin recognizing her tenacity. In 1986, Marilyn participated in the first clinical trial for Sandostatin.

Special thanks to Amy Matthew of The Pueblo Chieftain for sharing Marilyn's story of hope and positivity.  Read the article here.

Spotlight on Guest Bloggers for CCF

The Carcinoid Cancer Foundation is pleased to announce that we are going to feature guest contributors to our blog during 2015. Intelligent Patients – Just What the Doctor Didn’t Order by Ronny Allan, a carcinoid cancer patient from the UK, is our first guest blog post. Read the post here.